Mirtha Guitelman
University of Buenos Aires
EndocrinologyAcromegalyPituitary adenomaDiabetes mellitusMedicine
What is this?
Publications 38
#1Karina DanilowiczH-Index: 11
#2Soledad SosaH-Index: 1
Last. Fabián PitoiaH-Index: 14
view all 17 authors...
#1Mariana Fuertes (MPG: Max Planck Society)H-Index: 6
#2Julieta TkatchH-Index: 1
Last. Eduardo Arzt (Facultad de Ciencias Exactas y Naturales)H-Index: 39
view all 6 authors...
Cushing's disease (CD) is an endocrine disorder originated by a corticotroph tumor. It is linked with high mortality and morbidity due to chronic hypercortisolism. Treatment goals are to control cortisol excess and achieve long-term remission, therefore reducing both complications and patient’s mortality. First-line of treatment for CD is pituitary’s surgery. However, 30% of patients who undergo surgery experience recurrence in long-term follow up. Persistent or recurrent CD demands second line ...
2 CitationsSource
#1Adrian Daly (University of Liège)H-Index: 35
#2Emilie CastermansH-Index: 14
Last. Albert BeckersH-Index: 54
view all 12 authors...
10 CitationsSource
Resumen Introduccion El riesgo de desarrollar neoplasias colonicas en pacientes acromegalicos y su relacion directa con los niveles elevados de GH/IGF-1 no estan bien establecidos y continuan siendo motivo de controversia en la literatura mundial. El objetivo de este trabajo fue evaluar el riesgo de desarrollar lesiones neoplasicas avanzadas (LNA) (adenomas mayores a 1 cm, componente velloso mayor del 75% y/o displasia de alto grado), en pacientes con acromegalia, comparado con un grupo control....
Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average t...
4 CitationsSource
#1Annamaria ColaoH-Index: 83
Last. Mônica R. GadelhaH-Index: 30
view all 14 authors...
#1Mirtha GuitelmanH-Index: 9
#2F. SmithuisH-Index: 1
Last. Adriana Oneto (UBA: University of Buenos Aires)H-Index: 4
view all 6 authors...
Purpose Insulin-like growth factor I (IGF-I) represents an essential tool in the diagnostic work-up and in the monitoring of treatment efficacy for somatotrophic axis disorders both in children and adults. A large number of factors including, but not limited to, age, sex and weight as well as analytical variables influence IGF-I serum levels; therefore, reliable normative data are essential for a correct interpretation of results. The aim of the present study was to establish reference range val...
1 CitationsSource
#1Mônica R. Gadelha (UFRJ: Federal University of Rio de Janeiro)H-Index: 30
#2Marcello D. Bronstein (USP: University of São Paulo)H-Index: 31
Last. Annamaria ColaoH-Index: 83
view all 14 authors...
Summary Background Many patients with acromegaly do not achieve biochemical control despite receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide. In the PAOLA trial, we aimed to assess the efficacy and safety of two different doses of the somatostatin analogue pasireotide long-acting release compared with active control (octreotide or lanreotide) in patients with inadequately controlled acromegaly. Methods In a multicentre, randomised, phase 3 trial, we en...
146 CitationsSource